ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pearl, J. M.
Right arrow Articles by Duffy, J. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pearl, J. M.
Right arrow Articles by Duffy, J. Y.
Related Collections
Right arrow Myocardial protection

Ann Thorac Surg 2001;72:565-570
© 2001 The Society of Thoracic Surgeons

Original article: cardiovascular

Endothelin receptor blockade reduces ventricular dysfunction and injury after reoxygenation

Jeffrey M. Pearl, MDa, David P. Nelson, MD, PhDa, Connie J. Wagner, BSa, John P. Lombardi, CCPa, Jodie Y. Duffy, PhDa

a Division of Pediatric Cardiothoracic Surgery, Children’s Hospital Medical Center, Cincinnati, Ohio, USA

Accepted for publication April 19, 2001.

Address reprint requests to Dr Pearl, Division of Cardiothoracic Surgery, Children’s Hospital Medical Center, 3333 Burnet Ave, OSB 3, Cincinnati, OH 45229
e-mail: pearj0{at}chmcc.org

Background. Reoxygenation of hypoxic myocardium during repair of congenital heart defects results in poor ventricular function and cellular injury. Endothelin-1 (ET-1), a potent vasoconstrictor that increases during hypoxia, may suppress myocardial function and activate leukocytes. The objective was to determine whether administration of an endothelin receptor antagonist could improve ventricular function and decrease cardiac injury after hypoxia and reoxygenation.

Methods. Fourteen piglets underwent 90 minutes of ventilator hypoxia, 1 hour of reoxygenation on cardiopulmonary bypass, and 2 hours of recovery (controls). Nine additional animals received an infusion of Bosentan, an ET(A/B) receptor antagonist, (5 mg/kg per hour) during hypoxia and reoxygenation.

Results. Right and left ventricular dP/dt in controls decreased to 78% and 52% of baseline, respectively, after recovery (p < 0.05). In contrast, Bosentan-treated animals had complete preservation of RV dP/dt and less depression of LV dP/dt. Bosentan reduced the hypoxia and reoxygenation–induced elevation of ET-1 and iNOS mRNA at the end of recovery (p < 0.05). Bosentan-treated animals had diminished myocardial myeloperoxidase activity and lipid peroxidation compared with controls (p < 0.05). Myocardial apoptotic index, elevated by hypoxia and reoxygenation, was lower in the Bosentan-treated animals (p < 0.05).

Conclusions. Endothelin-1 receptor antagonism improved functional recovery and decreased leukocyte-mediated injury after reoxygenation. The reduction in cardiac cell death might also improve long-term outcome after reoxygenation injury.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Z. Xia, K.-H. Kuo, D. V. Godin, M. J. Walker, M. C. Y. Tao, and D. M. Ansley
15-F2t-isoprostane exacerbates myocardial ischemia-reperfusion injury of isolated rat hearts
Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1366 - H1372.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
D. Konrad, A. Oldner, M. Wanecek, A. Rudehill, E. Weitzberg, B. Biber, G. Johansson, S. Haggmark, and M. Haney
Positive inotropic and negative lusitropic effects of endothelin receptor agonism in vivo
Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1702 - H1709.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. B. Reece, V. E. Laubach, C. G. Tribble, T. S. Maxey, P. I. Ellman, P. S. Warren, A. M. Schulman, J. Linden, J. A. Kern, and I. L. Kron
Adenosine A2A Receptor Agonist Improves Cardiac Dysfunction From Pulmonary Ischemia-Reperfusion Injury
Ann. Thorac. Surg., April 1, 2005; 79(4): 1189 - 1195.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. M. Pearl, S. M. Schwartz, D. P. Nelson, C. J. Wagner, J. M. Lyons, S. M. Bauer, and J. Y. Duffy
Preoperative glucocorticoids decrease pulmonary hypertension in piglets after cardiopulmonary bypass and circulatory arrest
Ann. Thorac. Surg., March 1, 2004; 77(3): 994 - 1000.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
F. Eefting, B. Rensing, J. Wigman, W. J. Pannekoek, W. M. Liu, M. J. Cramer, D. J Lips, and P. A Doevendans
Role of apoptosis in reperfusion injury
Cardiovasc Res, February 15, 2004; 61(3): 414 - 426.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
W. M. Yarbrough, R. Mukherjee, G. P. Escobar, J. T. Mingoia, J. A. Sample, J. W. Hendrick, K. B. Dowdy, J. E. McLean, R. E. Stroud, and F. G. Spinale
Direct inhibition of the sodium/hydrogen exchanger after prolonged regional ischemia improves contractility on reperfusion independent of myocardial viability
J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1489 - 1497.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. Ruel, C. Bianchi, T. A. Khan, S. Xu, J. R. Liddicoat, P. Voisine, E. Araujo, H. Lyon, I. S. Kohane, T. A. Libermann, et al.
Gene expression profile after cardiopulmonary bypass and cardioplegic arrest
J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1521 - 1530.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2001 by The Society of Thoracic Surgeons.